Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,032 recruiting studies in this area right now.
By phase
- Not applicable2,815
- Phase 2751
- Phase 1525
- Phase 3381
- Phase 1/Phase 2297
- Phase 4204
- Phase 2/Phase 359
Top conditions
- Breast Cancer1,197
- Melanoma174
- Metastatic Breast Cancer138
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Breast Neoplasms111
- Triple Negative Breast Cancer110
- Colorectal Cancer95
- Ovarian Cancer91
- Psoriasis85
- Breast Carcinoma79
- Lung Cancer77
- Prostate Cancer70
- Rheumatoid Arthritis (RA)68
- Diabetic Foot Ulcer60
- Cancer58
- Systemic Lupus Erythematosus (SLE)52
Leading sponsors
- Fudan University64
- M.D. Anderson Cancer Center51
- Memorial Sloan Kettering Cancer Center49
- Novartis Pharmaceuticals48
- Mayo Clinic40
- AstraZeneca38
- Assistance Publique - Hôpitaux de Paris37
- National Cancer Institute (NCI)37
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University34
- Second Affiliated Hospital, Zhejiang University, School of Medicine30
Where studies are running
- California406
- Arizona150
- Alabama130
- Florida128
- New York110
- Texas106
- Maryland94
- Massachusetts86
- Pennsylvania72
- North Carolina68
Recruiting studies5,032 total
- NCT05587244Enrolling by invitation
Hip liner study for people getting a hip replacement
This study looks at a specific type of hip replacement liner (the part inside the hip joint) and how well it works after surgery. You might be eligible if you’re planning a one-sided hip replacement and don’t have certain infection, bone, or health problems that could affect healing.
Birmingham, AlabamaAges 18–80 - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT05573893Recruiting
Real-world study of trastuzumab deruxtecan for HER2 breast cancer
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
AmbergAges 18–130 - NCT05142475RecruitingEarly Phase 1
Study of GC101 tumor-infiltrating cells for advanced breast cancer
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
ShanghaiAges 18–75 - NCT05523947RecruitingPhase 1/Phase 2
Study drug for HER2-positive solid tumors, with dose changes
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Boston, MassachusettsAges 18 years+ - NCT05548972Enrolling by invitation
Follow-up study of a hip replacement to improve implant wear
This study checks how well a specific hip replacement bearing surface (called dual mobility with Vivacit-E or Longevity) performs over time in real-world patients. It may help people by tracking long-term safety and performance to guide better hip replacement choices.
Little Rock, ArkansasAges 18–80 - NCT04965064RecruitingPhase 2
Neratinib plus capecitabine for HER2-negative breast cancer brain mets
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
Rochester, New YorkAges 18 years+ - NCT05524480Enrolling by invitation
Help Latina women get overdue breast, cervical care
This trial tests an implementation program that helps clinics better provide breast and cervical cancer screening and HPV vaccination to Latina women who are behind on recommended care. It may help you catch up on screening or start HPV vaccination and connect you to low-cost services.
Houston, TexasAges 18–74 - NCT05534438RecruitingPhase 2
Tested targeted radiation plus usual drug treatment in metastatic breast cancer
This Phase 2 study tests whether adding a very focused type of radiation to standard drug treatment can better control metastatic breast cancer. It is for people whose cancer is only progressing in one spot, seen on a PET scan.
Basking Ridge, New JerseyAges 18 years+ - NCT05536856RecruitingPhase 4
5-fluorouracil skin treatment for stable, localized vitiligo
This trial tests a medicated skin powder placed on the skin to treat vitiligo that has been stable for at least a year. It may help people with localized vitiligo by trying to bring back normal skin color without changing their care mid-study.
CairoAges 10–70 - NCT05507879Recruiting
Breast cancer heart monitoring to predict heart damage risk
This trial studies how a blood test marker (TRPC6) may help predict and prevent heart muscle damage and heart failure related to some breast cancer medicines. You may join if you’re starting or have received treatment that can stress the heart, or if you already have signs of treatment-related heart problems.
Gainesville, FloridaAges 18 years+ - NCT05505643Recruiting
Cryoablation versus lumpectomy for early breast cancer
This trial compares two ways to remove early-stage breast tumors: freezing (cryoablation) or surgery (lumpectomy). It may help find which option works as well or better for cancer control while keeping the breast looking more natural for some people.
St Louis, MissouriAges 50 years+ - NCT05538208RecruitingPhase 2
Children with lupus kidney inflammation using mycophenolate
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
San Francisco, CaliforniaAges 8–20 - NCT05528133RecruitingPhase 2
Personalized radiation based on tumor genetics in triple-negative breast cancer
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
Clearwater, FloridaAges 18 years+ - NCT05507125Recruiting
Study of how inflammatory genes work in hidradenitis
This study looks at how certain body “inflammatory genes” behave in people with hidradenitis suppurativa. It may help researchers understand what drives this condition and how future treatments could be targeted.
Birmingham, AlabamaAges 18–89 - NCT05504707RecruitingPhase 1
Study drug for early-stage, HER2-negative, low-risk hormone breast cancer
This Phase 1 trial tests a new study drug called DC1 given before standard breast cancer treatments. It focuses on people with HER2-negative breast cancer that is “hormone negative” or “hormone low,” aiming to see if the treatment is safe and whether it may work before surgery or other local therapy.
Tampa, FloridaAges 18 years+ - NCT05524584RecruitingPhase 2
Anastrozole, fulvestrant, and abemaciclib for hormone-positive breast cancer
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
Orange, CaliforniaAges 18 years+ - NCT05532865Recruiting
Biobank study for adults with systemic sclerosis
This study follows adults with systemic sclerosis who are being seen at a specific hospital and asks for consent to store blood and other samples for future research. It may help researchers better understand the disease and develop better tests or treatments over time.
BrestAges 18 years+ - NCT05535192Recruiting
Telehealth strength exercise to help older women during breast cancer chemo
This study tests whether a supervised at-home (telehealth) strength exercise program can help older women stay strong and keep their chemotherapy on schedule. It’s meant for women who are starting chemotherapy for breast cancer with the goal of cure.
Boston, MassachusettsAges 65 years+ - NCT05522660RecruitingPhase 3
Immunotherapy or targeted therapy with focused brain radiation
This Phase 3 study tests whether immunotherapy or targeted medicine, with or without a one-time focused brain radiation procedure, can control brain metastases from melanoma or non-small cell lung cancer. It mainly enrolls people who have no (or minimal) brain symptoms and are newly diagnosed in the brain (except for certain recent brain surgery).
NaplesAges 18 years+ - NCT05512364RecruitingPhase 3
Elacestrant for ER-positive, HER2-negative breast cancer with ctDNA relapse
This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.
AnderlechtAges 18 years+ - NCT01962415RecruitingPhase 2
Reduced-intensity stem cell transplant for non-cancer disorders
This trial tests whether a gentler (reduced-intensity) conditioning treatment before a stem cell transplant works for non-cancer diseases. It uses specific donor stem cell matches and checks heart, lung, liver, and kidney function to help lower transplant stress while still aiming for benefit.
Pittsburgh, PennsylvaniaAges 2 months–55 years - NCT04563507RecruitingPhase 2
Immunotherapy plus hormone therapy for metastatic ER-positive breast cancer
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
New York, New YorkAges 18–90 - NCT05492799Enrolling by invitationPhase 4
Study of AX 250 for MPS IIIB in children
This Phase 4 trial studies how safe, tolerable, and helpful ICV AX 250 is for people with MPS IIIB. It is for participants who already finished a prior AX 250 study and meet specific health and eligibility checks.
Oakland, CaliforniaAges Any age
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,032 recruiting dermatology studies from the U.S. registry right now, out of 7,856 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.